Prediction of relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: external validation of the MOG-AR score
In a UK-MOGAD cohort, MOG-AR score showed suboptimal performance in predicting relapse over a 3-year period from onset. Further work to find clinically accessible predictive biomarkers and tools for a relapsing course would facilitate better treatment strategies near disease onset.
Authors
- J. Palace
- Helmut Butzkueven (ORCID: https://orcid.org/0000-0003-3940-8727)
- Wei Zhen Yeh (ORCID: https://orcid.org/0000-0002-5335-6612)
- Anna Francis
- M Isabel Leite
- Ruth Geraldes
Institutions
- John Radcliffe Hospital (GB)
- University of Oxford (GB)
- Alfred Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1007/s00415-026-13754-9
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00